[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nottingham University Hospitals NHS Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":324},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,38,63,90,118,144,176,206,235,258,281,301],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100448744","longitudinal-assessment-of-iron-rims-in-ms-lesions-100448744",false,"NCT05123443","Longitudinal Assessment of Iron Rims in MS Lesions","Longitudinal Assessment of Iron Rims in White Matter MS Lesions as a Marker of Disability","Inclusion Criteria:\n\n* Men and women aged above 16 years\n* Clinical diagnosis of MS as per revised McDonald Criteria 2017\n* Existing susceptibility-weighted brain MRI scan\n* Able to provide blood samples\n\nExclusion Criteria:\n\n* Unwilling or unable to comply with the requirements of this protocol including the presence of any condition (physical, mental or social) that, in the opinion of the PI, is likely to affect the participants ability to comply with the study protocol.\n* Unable to provide informed consent.","ALL","16 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","In multiple sclerosis (MS), the presence of white matter lesions surrounded by a rim of iron is suggested to signify a more severe disease course. Iron rim lesions can be detected through their appearance on susceptibility-based brain MRI at either 3-Tesla or 7-Tesla strength. We know that the formation of chronic active lesions is not uniform across MS cohorts so identifying risk factors which predispose individuals to the formation of rim lesions may provide a useful biomarker for clinical progression. One candidate set of risk factors include genetic variants which prevent some MS patients from resolving acute inflammation following their initial wave of inflammatory demyelination at lesion onset.\n\nAdditionally, only small longitudinal clinical cohorts have reported the evolution of iron rim lesions many years after their initial formation, as well as their link to clinical disability or disease progression.\n\nNUH hold 7T-MRI scans of over 100 patients who received a research MRI with iron-sensitive sequences between 2008-2012. We will recruit 100 patients that received brain MRI several years ago to provide blood samples. The blood samples along with the previously acquired MRI scan will be sent to Johns Hopkins University in the US where genotyping studies will be performed to explore whether this genetic variation contributes to the accrual of chronic active rim lesions in MS. Patients who consent to provide blood samples will also have the option to consent to receive an additional 7-Tesla MRI scan which will allow us to compare how rim lesions evolve and whether their presence is correlated with disability. 30 MRI scans will initially be performed as funding for this amount is already secured.\n\nFollowing analysis of the pilot phase 1 data and securing additional funds, we will contact more patients who have already consented to receive the additional MRI to receive the scan",[24],"Multiple Sclerosis","RECRUITING","2026-03-10",{"date":28,"type":29},"2026-03-12","ACTUAL",{"date":31,"type":29},"2022-09-03",{"date":33,"type":20},"2027-07-31",{"name":35,"class":36},"Nottingham University Hospitals NHS Trust","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":37},"100569057","faecal-immunochemical-tests-fit-for-surveillance-after-colorectal-cancer-crc-study-100569057","NCT06689293","Faecal Immunochemical Tests (FIT) for Surveillance After Colorectal Cancer (CRC) Study","FITS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histological diagnosis of colorectal carcinoma\n* Previously treated by surgical resection with curative intent for colorectal carcinoma\n* Due whole-colon investigation for CRC follow-up as part of local routine care (Colonoscopy or CT colon)\n\nExclusion Criteria:\n\n* Patients under the age of 18\n* Patients unable to give valid informed consent\n* Patients with a current ileostomy, or no remaining colon after their operation (patients with colostomy will not be excluded)\n* Patients already diagnosed with recurrence of their colorectal cancer","18 Years",{"count":47,"type":20},1000,"In the United Kingdom, over 25,000 patients have an operation for bowel cancer each year. After their operation, patients are monitored with a colonoscopy (camera test of the bowel) approximately 3 years after their operation, to look for any possible return of the cancer. Colonoscopies, and the bowel-cleaning medications needed, can be unpleasant for patients.\n\nThe Faecal Immunochemical Test (FIT) is a test to look for blood hidden in the poo. Blood in the poo can be a sign of bowel cancer, or a growth that can turn in to a cancer if left untreated (polyps). We currently use this test for bowel cancer screening, and to assess the risk of cancer in patients with bowel symptoms. You may have had a FIT when having tests for bowel cancer. We know this test is effective in picking up bowel cancer in these cases, but its use has not been assessed in following-up patients who have had treatment for bowel cancer previously.\n\nFor this study, we aim to see if a FIT stool sample test is accurate at diagnosing a return of bowel cancer for patients who have had a previous operation for bowel cancer. We want to see if using FIT could 'rule-out' cancer for some patients and be a potential alternative to colonoscopy for some patients in the future, allowing them to avoid this sometimes unpleasant test, which patient groups have told us is important for them.\n\nPatients taking part in this study will have their usual treatment, including their colonoscopy (or sometimes a scan of the bowel), but will be asked to also provide a single FIT sample to assess how accurate this test is. The FIT sample is a quick and easy test of the poo that you can take at home and send to Nottingham University Hospitals NHS Trust (NUH) for testing. It should take no more than 5 to 10 minutes to take the sample, and a prepaid envelope is included to send the sample back to NUH for testing.\n\nWe aim to include at least 1,000 patients across 7 hospital trusts in the East Midlands.",[50],"Colorectal Cancer (CRC)",[52,53,54],"colorectal","Faecal Immunochemical Testing (FIT)","surveillance","2026-01-20",{"date":57,"type":29},"2026-01-21",{"date":59,"type":29},"2025-02-28",{"date":61,"type":20},"2027-06-23",{"name":35,"class":36},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":37},"100561244","virtual-technology-to-improve-the-management-of-perianal-crohn39s-vamp---prospective-100561244","NCT06587646","VirtuAl Technology to Improve the Management of Perianal Crohn's (VAMP) - PROSPECTIVE","A Feasibility Study to Assess a "Virtual" (vEUA) Technology to Improve the Management of Perianal Crohn's Disease","VAMP-PROSPECT","Inclusion Criteria:\n\n* Ability to give informed consent\n* Active perianal Crohn's disease as defined by clinical assessment with fistula or abscess formation\n* A clinical decision has been taken that surgery is required for perianal disease\n* Ages of 18-75\n\nExclusion Criteria:\n\n* Inability to consent\n* history of Proctectomy,\n* absence of a diagnosis of Crohn's disease,\n* perianal fistulising disease not secondary to Crohn's disease,\n* Rectovaginal fistulas\n* Malignant disease\n* Significant cardiovascular or respiratory disease\n* Neurological or cognitive impairment\n* Significant physical disability\n* Significant hepatic disease or renal failure\n* Subjects currently (or in the last three months) participating in another research project\n* Pregnancy or breastfeeding\n* If MRI is contraindicated (e.g. pacemaker).\n* under 18 years old or over 75 years old","75 Years",{"count":73,"type":20},30,"INTERVENTIONAL",[76],"NA","Crohn's is an inflammatory condition that can affect any part of the gut. Over half a million people in the UK live with Crohn's disease and about a quarter will develop a fistula near their back passage. A fistula is an abnormal connection between two surfaces of the body. These can be hard to treat causing pain and infection. Surgery is required to control infection and in extreme cases this can lead to incontinence or even formation of a stoma, when the bowel is brought to the skin and waste goes into a bag on the tummy wall.\n\nPatients with perianal Crohn's are usually referred to a surgeon by their medical team and subsequently undergo a MRI scan and an examination under anaesthesia (EUA) where abscesses (regions of fluid build-up) will be drained and a seton (plastic sling or suture) inserted through the fistula, or the fistula opened to the skin if this will not affect continence. They are then started on specialist medication by the gastroenterologists (gut doctors).\n\nAbscesses or fistulas can be difficult to identify during EUA, leading to ongoing infection and repeat procedures. This causes additional scarring and delays the medical treatment that can allow fistulas to heal. Multiple or incorrectly performed operations can also damage the muscles that help hold stool in the back passage, leading to incontinence.\n\nWe believe that improving how information is communicated between radiology (who report scans) and surgeons will improve their ability to identify and manage all fistulas and collections at operation. Here is a typical MRI report given to the surgeon by the radiologist:\n\n\\'There is a low intersphincteric fistula with predicted internal opening in the lower half of the anal canal at dentate line level between 5-6 o'clock that passes in the intersphincteric plane to the anal verge between 5-6 o\\'clock.\\'\n\nThis protocol was developed in an era when written communication was really the only way to convey information between specialists. Jargon aside, surgeons face significant difficulty interpreting such written descriptions of a complex 3D structure and using it as a surgical guide. Indeed, a major complaint from surgeons is how difficult it is to get real value from these preoperative MRIs, which cost time and money.\n\nWith advances in digital technology, we believe this system can be vastly improved.\n\nMotilent (a UK SME specialising in technology to improve the management of Crohn\\'s Disease) has developed a sophisticated visualisation tool to provide a 3D model of the fistula and surrounding structures, we call this tool Virtual EUA (vEUA), allowing the surgeon to better understand the anatomy of the problem in conjunction with radiology.\n\nWe are aiming to establish whether vEUA changes the behaviour of colorectal surgeons, increasing confidence in identifying and dealing with fistulas, which will reduce the number of surgical procedures required and improve the quality of care, resulting in a cost saving for the hospital and a much-needed step towards more effective management of perianal Crohn\\'s.\n\nAny patient taking part in the trial will be randomly allocated to have the 3D model utilised in their care or standard care. We will use pre- and post-surgical patient questionnaires, surgical questionnaires and MRI imaging to establish if vEUA is safe and effective in improving the care of patients with perianal Crohn\\'s.",[79],"Perianal Crohns Disease",[81,82,83],"Perianal Crohn's Disease","3D imaging","MRI",{"date":57,"type":29},{"date":86,"type":29},"2024-07-23",{"date":88,"type":20},"2026-09-07",{"name":35,"class":36},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":37},"100616281","prevention-of-pressure-injury-pi-in-hospitalised-infants-children-and-young-people-cyp-aged-0-19-years-100616281","NCT07303569","Prevention of Pressure Injury (PI) in Hospitalised Infants, Children, and Young People (CYP) (Aged 0-19 Years)","CYPPI","Inclusion Criteria:\n\nPhase 1\n\nHCP participants:\n\n1. Experts (e.g. tissue viability practitioners, dermatologist)\n2. HCP looking after hospitalised infants and CYP\n3. Able to give consent\n\nParent\u002F guardian participants:\n\n1. Parents\u002F guardians of infants and CYP admitted to hospital with or developed PI\n2. Parent\u002F guardian of a CYP under 19 years of age with dark skin tone according to Fitzpatrick Classification of Skin Types III, IV, V or VI.\n3. Able to give consent\n\nCYP participants:\n\n1. Age 10 - 19\n2. Dark skin tone according to Fitzpatrick Classification of Skin Types III, IV, V or VI.\n3. Able to gain consent\n4. Able to provide assent with parental consent\n5. Developed PI during hospitalisation Phase 2 Hospitalised infants and CYP participants\n\n1\\. Infants and CYP admitted to hospital for 24 hrs 2. Age 0-19 years 3. Able to gain consent. 4. Fitzpatrick Classification of Skin Types IV, V or VI.\n\nExclusion Criteria:\n\nPhase1:\n\nHCP participants:\n\n1. HCP not working with hospitalised infants and CYP.\n2. Unable to provide consent.\n\nParents participants:\n\n1. Parents of hospitalised infants and CYP with no PI.\n2. Unable to gain consent\n\nCYP participants:\n\n1. Not able to provide consent\n2. CYP with no PI during hospitalisation period Phase 2\n\n1\\. Admitted to hospital for less than 24 hrs 2. Unable to gain consent 3. Fitzpatrick Classification of Skin Types I, II or III",true,{"count":99,"type":20},542,"What is the problem? Children and young people admitted to hospital can sometimes be harmed by what is called a pressure injury. Pressure injuries are sores (ulcers) that happen on areas of the skin that are under pressure. The pressure can come from lying in bed, sitting in a wheelchair, or wearing a cast for a long time. They usually form on bony parts of the body, such as the heels, elbows, hips, and tailbone. This can be uncomfortable for the patient and distressing for their families. As well, it means that more staff and treatments are needed for the patient.\n\nWhat is known? There is a difference in pressure injury seriousness for infants and children with dark skin tones to those without. Pressure injury care for hospitalised patients starts with an assessment using a tool. In the past, the assessment tools were developed without consideration for differences due to skin tone. This means that the current tools may not be the best way to identify pressure injury for dark skin tones. Healthcare professionals need to make sure that tools are fit for purpose for all.\n\nWhat are investigators going to do? Investigators will work with healthcare professionals, children, and parents together to develop and test the existing pressure injury risk assessment tool for use with dark skin tones.\n\nThis study is a result of care priority discussions with parents and children. It came from the patients and will benefit the patients. Children, young people, and parents will be involved throughout to ensure their voices are heard.\n\nHow are investigators going to do it?\n\nInvestigators will:\n\n1. Look at existing information about pressure injury for children with darker skin tones. If required, investigators will change and increase the accuracy of the existing tool.\n2. Test the modified risk assessment tool at 10 children's hospitals in the UK. Investigators will do this to see if it can distinguish hospitalised children with dark skin tones, at high or low risk of pressure injury development during their hospital stay.",[102,103],"Pressure Injuries","Pressure Ulcers, Bedsores, Decubitus Ulcer",[105,106,107,108,109],"Pressure Injury prevention","assessment","tools (instruments)","Validity","Dark skin tone","2025-12-10",{"date":112,"type":29},"2025-12-26",{"date":114,"type":29},"2025-07-30",{"date":116,"type":20},"2026-05-16",{"name":35,"class":36},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":97,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":37},"100603421","seizure-identification-on-the-intensive-care-unit-icu-100603421","NCT07136298","Seizure Identification on the Intensive Care Unit (ICU)","Seizure Semiology Identification and Agreement in the Intensive Care Setting: How do Clinical Scientists Compare to Other Healthcare Professionals (Intensivists, Neurologists, ITU Nurses and Neurophysiologists) in Identifying and Interpreting Clinical Signs in Patients on the Adult Intensive Care Unit","Inclusion Criteria:\n\nStaff working at Nottingham University Hospitals (NUH) in one of the following staff groups;\n\n* Neurophysiology Scientists\u002FClinical Physiologists at Band 7 level and above,\n* Neurophysiologists who have completed the CCT in Neurophysiology with at least 1 year of Adult ICU experience.\n* members of the Neurology medical team with at least 1 years' experience of covering ITU\n* Intensivists with at least 1 year's experience working on the Adult intensive care unit\n* Nursing staff working on the Intensive care unit with at least 1 year's experience\n\nExclusion Criteria:\n\n* Staff not employed by NUH i.e. agency staff\n* Staff in other groups not mentioned above",{"count":126,"type":20},40,"The aim of this project is to assess the ability of different groups of National Heath Service (NHS) professionals to correctly identify clinical seizures, and distinguish them from other movements commonly seen in the ICU environment, when shown digital video recordings only.\n\nPatients on the ICU are at risk of having seizures, however also commonly make other movements, including shivering, jerking, tics and tremors. An Electroencephalogram (EEG) records the brain wave activity and can help distinguish epileptic seizures from other movements. In a study by Bendadis et al (2010), 52 video-EEGs were reviewed containing \"possible seizures\" on the ICU. They found only 27% recorded actual epileptic events, with the other 73% having a range of other movements. Malone et al (2009) studied accuracy of diagnosis of 20 video recordings of clinical episodes on the neonatal unit, comparing different staff groups. They found no significant difference between Doctors and Nurses in correctly identifying seizures, however found that accuracy of diagnosis was generally poor.\n\nClinical scientists are currently expanding their roles and responsibilities across Neurophysiology, including giving consultant-level advice on EEG investigations. EEG recordings on the ICU are often obscured by excessive, unavoidable electrical\u002Fmovement artefacts caused by equipment such ventilators and pumps, and patient factors such as position, breathing artefact and suctioning. These make the EEG difficult to interpret (Boggs 2021). Assessing the clinical signs and symptoms which we may see in ICU patients, in the absence of interpretable EEG, is an essential skill.\n\nThis study aims to assess Clinical Scientists skills at clinical interpretation, in comparison with other staff groups in the ICU setting. Staff will be asked to watch video clips of events captured in the ICU, and tell us whether they think they are seizures or not, and explain their thought process behind the decision.",[129],"Seizures",[131,132,133,134,135],"Intensive Care","Clinical Scientist","Neurologists","Intensivists","ITU Nurses","2025-08-14",{"date":138,"type":29},"2025-08-22",{"date":140,"type":29},"2025-03-03",{"date":142,"type":20},"2025-08-31",{"name":35,"class":36},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":74,"phases":156,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":37},"100560069","low-energy-diet-in-adolescents-with-obesity-and-type-2-diabetes-the-legend-study-100560069","NCT06572345","Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study","A Multicentre Open-Label, Feasibility Study of the Use of a Short-Term Low-Energy Diet in Adolescents With Obesity and Type-2 Diabetes Mellitus","LEGEND","Inclusion criteria\n\nLED intervention\n\n* Diagnosis of T2DM (defined as an HbA1C ≥48mmol\u002Fmol, in the absence of features of type 1 or monogenic\u002Fsyndromic diabetes).\n* Current HbA1C ≥48 (or ≥42 on antidiabetic medication) and ≤ 80 mmol\u002Fmol.\n* Aged 12 to 17 years old.\n* BMI ≥98th centile (+2 SD) for age and sex (UK90 growth reference data).\n* Informed consent:\n\n  * Received from the young person (age 16-17) OR\n  * Received from young person's parent\u002Fcarer, with patient assent (age 12-15).\n* Willing to engage in and commit to low energy diet, FR and weight management phases including follow-up and attending study visits.\n\nLED Intervention Interviews\n\nThe same interview inclusion criteria for LED intervention, with the following additional requirements:\n\nPatients:\n\n* Informed consent:\n\n  * Received from the young person (age 16-17) OR\n  * Received from young person's parent\u002Fcarer, with patient assent (age 12-15).\n* Willing to take part in a qualitative interview alongside a parent\u002Fcarer.\n\nRelative\u002FCarer:\n\n* A relative\u002Fcarer for a young person meeting the above LED participant eligibility criteria.\n* Informed consent from the relative\u002Fcarer to participate in the interview.\n* Willing to take part in a qualitative interview alongside the young person.\n\nNon-LED Qualitative Interview only participants\n\n* Diagnosis of T2DM (defined as an HbA1C ≥48mmol\u002Fmol, in the absence of features of type 1 or monogenic\u002Fsyndromic diabetes).\n* Current HbA1C ≥48 (or ≥42 on antidiabetic medication) and ≤80 mmol\u002Fmol.\n* Aged 12 to 17 years old.\n* BMI ≥98th centile (+2 SD) for age and sex (UK90 growth reference data).\n* Informed consent:\n\n  * Received from the young person (age 16-17) OR\n  * Received from young person's parent\u002Fcarer, with patient assent (age 12-15).\n* Willing to take part in a qualitative interview alongside a parent\u002Fcarer only.\n\nHCPs\n\n* Registered HCP.\n* Experience of delivering this trial to the adolescents.\n* Willing to take part in a qualitative interview about undertaking motivational interviewing training and conducting\u002Fdelivering the LED intervention study.\n\nExclusion criteria\n\nLED intervention\n\n* HbA1C greater than 80mmol\u002Fmol.\n* Presence of diabetes-related autoantibodies, as per local centre guidelines.\n* Confirmed mono-genetic cause of obesity (e.g. SIM1 mutation) or diabetes-associated syndrome such as Prader-Willi syndrome, Bardet-Biedl or Wolfram's syndrome.\n* Secondary diabetes (post bone marrow transplant\u002Fchemotherapy).\n* Significant psychiatric co-morbidity.\n* Breastfeeding, pregnant or planning to conceive during the LED and FR phases (female participants will be advised on need for effective contraceptive methods during the 12-month study period, section 5.1.1.10).\n* Any other condition which, in the opinion of the study investigator, would make it inappropriate to undertake a period of LED. (All reasons for not approaching patients will be recorded and analysed anonymously. Cases can be discussed with the core study group if there is doubt).\n* Participation in another interventional trial within 6 months.\n* Informed consent and\u002For assent not received.\n* Pre-existing retinopathy.\n* Dietary avoidance (including, but not limited to, due to allergies, intolerances, religious reasons and lifestyle choices) to any ingredients in the meal replacement products, including lactose.\n* Previous scoliosis repair.\n\nNon-LED Qualitative Interview only participants\n\n* HbA1C greater than 80mmol\u002Fmol.\n* Presence of diabetes-related autoantibodies, as per local centre guidelines.\n* Confirmed mono-genetic cause of obesity (e.g. SIM1 mutation) or diabetes-associated syndrome such as Prader-Willi syndrome, Bardet-Biedl or Wolfram's syndrome.\n* Secondary diabetes (post bone marrow transplant\u002Fchemotherapy).\n* Significant psychiatric co-morbidity.\n* Breastfeeding, pregnant or planning to conceive during the LED and FR phases (female participants will be advised on need for effective contraceptive methods during the 12-month study period, section 5.1.1.10).\n* Any other condition which, in the opinion of the study investigator, would either make it inappropriate to undertake a period of LED. (All reasons for not approaching patients will be recorded and analysed anonymously. Cases can be discussed with the core study group if there is doubt).\n* Participation in another interventional trial within 6 months.\n* Informed consent and\u002For assent not received.\n* Pre-existing retinopathy.\n* Dietary avoidance (including, but not limited to, due to allergies, intolerances, religious reasons and lifestyle choices) to any ingredients in the meal replacement products, including lactose.\n* Previous scoliosis repair.\n\nHCPs\n\n• None.","12 Years","17 Years",{"count":155,"type":20},73,[76],"This is a multicentre, single-arm, feasibility study in adolescents with T2DM and obesity to investigate the recruitment and retention rates to a study using Low Energy Diets(LED). It will also provide estimates of weight loss needed to bring about remission to inform a larger randomised study. In addition a subgroup of participants and their parents\u002Fcarers undertaking a period of LED will be interviewed to understand the participants experience of taking part. Two further groups will also be interviewed: participants and their parents\u002Fcarers who have declined to take part in the LED to understand their motivations and barriers and healthcare practitioners who have participated in conducting the trial to understand their experience of the study.",[159,160],"Pediatric Obesity","Type 2 Diabetes",[162,163,164,165,166,167],"Type 2 diabetes mellitus","Paediatric","Obesity","Low-energy diet","Adolescent","Remission","2025-08-01",{"date":170,"type":29},"2025-08-03",{"date":172,"type":29},"2025-06-30",{"date":174,"type":20},"2026-12-31",{"name":35,"class":36},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":185,"conditions":186,"keywords":192,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100494187","neurological-recovery-following-nos-sacd-100494187","NCT05714917","Neurological Recovery Following NOS-SACD","Longitudinal Assessment of Neurological Recovery in Patients Following Nitrous Oxide Abuse","Inclusion Criteria:\n\n* Any patient first presented with paraesthesia, weakness, ataxia or gait disturbance with a history of NOS use (age limit 16-40) as of 19\u002F08\u002F2024\n* Patients who can read and write in English, so that they can complete the questionnaires.\n* Patients must have received a definitive consultant neurologist confirmed diagnosis of NOS-induced neurological damage. This is possible as all eligible patients will have been reviewed by the neurology team prior to study involvement.\n\nExclusion Criteria:\n\n•Other causes of previous neuropathy or neurodegeneration indicated.\n\nQualitative Interview Study:\n\n* Patients currently taking part in the longitudinal study.\n* Patients who report previously (clinical history) or currently (PHQ-2, clinical history) experiencing mental health difficulties.","40 Years",{"count":19,"type":20},"Nitrous oxide has become an increasingly popular recreational drug amongst young people, particularly at festivals, nightclubs and parties. Considering the drug is not illegal to possess, has low cost in the form of 'whippets' and can be easily purchased online, it has become the second most commonly used recreational drug amongst people aged 16-24 in the UK. However, nitrous oxide is known to irreversibly inactivate the functioning of vitamin B12, a vitamin required for the maintenance and proper functioning of nerves in the spinal cord. Neurological symptoms in this population have been reported in around 3.4% of nitrous oxide users, although the true incidence is expected to be higher as the cases being reported by UK hospitals continues to rise.\n\nPatients may present with adverse neurological symptoms like tingling, weakness, coordination and mobility problems. Currently, studies reviewing the functional recovery of these patients have been limited by a retrospective study design, short follow up duration and being limited to small cohort sizes. This is in part linked to patient non-compliance and non-attendance at follow-up appointments. The investigators will therefore prospectively recruit all patients presenting with these symptoms and continue to collect data relating to their neurological recovery for 12 months. Data collection will be remote to ensure it is of low burden to the participants. This will allow the investigating team and others to fully appraise the severity of these toxic neuropathies and understand how best to manage their follow up.",[187,188,189,190,191],"Nitrous Oxide Abuse","Subacute Combined Cord Degeneration","Neurologic Symptoms","Paresthesia","B12 Deficiency Vitamin",[193,194,195,196],"Nitrous oxide","B12","Neurological symptoms","Clinical recovery","2025-07-22",{"date":199,"type":29},"2025-07-25",{"date":201,"type":29},"2024-08-19",{"date":203,"type":20},"2026-08-19",{"name":35,"class":36},3,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":74,"phases":215,"briefSummary":216,"conditions":217,"keywords":222,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100598908","the-feasibility-and-acceptability-of-an-online-yoga-program-for-people-with-functional-neurological-disorders-100598908","NCT07077603","The Feasibility and Acceptability of an Online Yoga Program for People With Functional Neurological Disorders","Acceptability and Feasibility of an Online Yoga Programme for Adults With a Functional Neurological Disorder.","YOGA-FUND","Inclusion Criteria:\n\n* Participants able to give informed consent.\n* Aged 18 years and over.\n* Participants with a confirmed clinical diagnosis of functional neurological disorder with dissociative seizures.\n* Access to WiFi and an electronic device on which to view and participate in the yoga programme.\n\nExclusion Criteria:\n\n* Participants with severe fatigue that would prevent engagement for the duration of the intervention (assessed by clinical neurology team member).\n* Participants who regularly practice yoga i.e., participants who practice each week.\n* People with a confirmed concurrent diagnosis of epilepsy.",{"count":73,"type":20},[76],"This is a feasibility study to see if it is acceptable and helpful for people living with a functional neurological disorder to receive online group yoga sessions to improve their wellbeing",[218,219,220,221],"Functional Neurological Disorder","Dissociative Seizures","Psychogenic Seizure","Non-Epileptic Seizure",[223,224,225,226],"dissociative seizure","functional neurological disorder","psychogenic seizure","yoga","NOT_YET_RECRUITING","2025-07-11",{"date":197,"type":29},{"date":231,"type":20},"2025-08",{"date":233,"type":20},"2026-06",{"name":35,"class":36},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100597050","the-impact-of-treatment-for-chronic-hepatitis-b-virus-on-non-clinical-harms-100597050","NCT07053449","The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical Harms","The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical (Social) Harms Amongst Migrant Populations: A Qualitative Study. (B-SOCIAL)","B-SOCIAL","Inclusion Criteria:\n\n* Chronic HBsAg\n* Able to give informed consent in English\n* Able to converse in English\n* Any migrant population member (non-UK) including if born overseas or in the UK\n* Aged 18 years and over\n* Has never taken antiviral treatment for HBV (12-15 participants)\n* Prescribed and taking any oral treatment for HBV for a minimum of 12 months (12-15 participants)\n\nExclusion Criteria:\n\n* Emotionally distressed due to HBV diagnosis\n* Current episode of decompensated cirrhosis\n* Current diagnosis of hepatocellular carcinoma",{"count":73,"type":20},"The goal of this qualitative study is to explore the impact of antiviral treatment, or none, for chronic hepatitis B virus on the non-clinical (social) harms experienced by migrant populations living in the UK.\n\nTwo groups of participants living with hepatitis B virus will be interviewed, those taking the daily treatment, and those not prescribed any treatment.",[246],"Hepatitis B Virus (HBV)",[248,249,250,251],"Hepatitis B Virus","Qualitative","Lived Experience","Stigma",{"date":253,"type":29},"2025-07-16",{"date":231,"type":20},{"date":256,"type":20},"2026-03",{"name":35,"class":36},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":4},"100550075","pneumocystis-jirovecii-genotyping-100550075","NCT06442345","Pneumocystis Jirovecii Genotyping","Real-time Pneumocystis Jirovecii Genotyping to Support Clinical Decision Making in the Management of Nosocomial Outbreaks","Inclusion Criteria:\n\n* Total nucleic acid extracts from adult patients (over 18 years old) with a positive PCP diagnosis (\\& detected at \\> 50 copies\u002F10ul) from routine respiratory panel testing.\n\nExclusion Criteria:\n\n* Total nucleic acid extracts from patients with a negative PCP diagnosis from routine respiratory panel testing\n* Total nucleic acid extracts from non-adult patients (under 18 years old).\n* PCP positive total nucleic extract samples with \\\u003C 50 copies\u002F10ul.\n* Patients included on the UK National Opt-Out register",{"count":266,"type":20},70,"We share our lives with microorganisms, and these generally do not pose a problem if an individual is healthy with a normal immune system. However, if the immune system was not functioning properly (e.g., cancer patients), they are at risk of infection. One microorganism, a fungus called Pneumocystis jirovecii (PCP), can cause severe chest infections in patients without properly functioning immune systems, leading to hospitalisation and death if untreated. If patients remain without a functioning immune system, they have a greater chance of repeated infection.\n\nPCP spreads through air from person-to-person and can survive on environmental surfaces. Patients can be infected after contact with these surfaces. Hospitals have a responsibility to ensure PCP infected patients do not pass it on to other unwell patients. In cases where PCP has infected multiple patients, knowing if the same fungi has been passed along (or transmitted) from patient-to-patient is vital in understanding if there is an outbreak in the hospital. Understanding how similar (the relatedness) the PCP strain is allows healthcare workers to detect any transmission between patients or the environment.\n\nTo understand how related each patient's PCP infection is we will utilise a laboratory test called multilocus sequence typing (MLST). This test looks at sections of the fungi's genetic code using deoxyribonucleic acid (DNA) sequencing to create a code (genotype) which tells us how related one PCP is to others tested, allowing comparison between patients and ultimately spotting transmission.\n\nOur aim is to develop this sequencing test using PCP positive patient samples and ensure it performs to high-quality standards. Surplus material from seventy known PCP positive patient samples will be tested. Each sample will be analysed to see if the DNA genotype matches or is similar to other patient samples we have tested, helping to understand how PCP may spread between patients.",[269],"Pneumocystis Pneumonia",[271,272],"PCP","Genotyping","2025-06-24",{"date":275,"type":29},"2025-06-27",{"date":277,"type":20},"2025-09",{"date":279,"type":20},"2026-01",{"name":35,"class":36},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":37},"100493234","assessing-the-presence-of-ct-dna-in-lymphoma-associated-hlh-100493234","NCT05702502","Assessing the Presence of CT-DNA in Lymphoma Associated HLH","Liquid Biopsy for the Identification of Malignancy Associated Haemophagocytic Lymphohistiocytosis (HLH)","Inclusion criteria:\n\n* Informed consent.\n* Age ≥18 years.\n* Clinically confirmed HLH.\n* High dose steroids and\u002For systemic anti-cancer therapy (SACT) for \\\u003C72 hours for the current episode of HLH (anakinra is not considered SACT). Prior steroid use \\>14 days at the time of consent is permitted.\n* Patients with recurrent HLH may be included.\n* Patients already known to have underlying lymphoma, or have relapsed lymphoma may be included.\n\nExclusion criteria:\n\n• Cause of HLH already known to be due to a non-malignant cause.",{"count":5,"type":20},"Haemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening blood disease which causes severe inflammation with symptoms similar to severe sepsis. It is hard to diagnose. The most common cause of HLH in adults is lymphoma (blood cancer). Outcomes for adults with HLH and cancer are serious, and most die after days or weeks because they have been diagnosed or treated too late. It is likely that many cases where patients died of HLH with no underlying cause actually had cancer.\n\nRecently it has been found that patients with certain types of lymphoma have DNA which comes directly from their cancer (circulating tumour DNA; ctDNA). Aggressive lymphomas release a lot of ctDNA which can be detected in the blood of patients. This study will look for ctDNA in patients with HLH, and see if it is possible to use it to diagnose lymphoma earlier. Patients will provide a small additional blood sample for analysis. Diagnosing lymphoma more rapidly would mean more people could get the correct treatment for the lymphoma which has caused their HLH. They could receive the correct treatment sooner. Earlier diagnosis and treatment could improve survival for these patients.",[291,292],"Lymphoma","Haemophagocytic Lymphohistiocytosis","2025-04-04",{"date":295,"type":29},"2025-04-08",{"date":297,"type":29},"2023-06-30",{"date":299,"type":20},"2026-01-01",{"name":35,"class":36},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":309,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":322,"locationsCount":323},"100469205","dolce-determining-the-impact-of-optellums-lung-cancer-prediction-solution-100469205","NCT05389774","DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution","DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction (LCP) Artificial Intelligence Solution on Service Utilisation, Health Economics and Patient Outcomes","DOLCE","Inclusion Criteria:\n\nPatients are eligible for the study if all of the following apply:\n\n* Are aged 35 years or above\n* Have baseline CT study with at least one incidentally detected solid or part-solid (must have a solid component \\>=80%) pulmonary nodule that:\n\n  * is not fully calcified\n  * Is 5-30mm inclusive in maximum axial diameter for the whole lesion measured using manual electronic callipers\n* Have baseline CT study that includes at least one series that meets all of the following (training for this will be provided):\n\n  * Is of a type that meets VNC instructions for use\n  * Comprises at least one full-inspiration breath-hold scans without a high degree of contrast media and does not exhibit quality issues (e.g., motion artefacts)\n\nExclusion Criteria:\n\nPatients will be excluded from the study if any of the following apply:\n\n* Have received a diagnosis for cancer in the last 5 years\n* Have thoracic implants that impact the image appearance of the nodule\n* Have more than five reported pulmonary nodules of any size or type excluding fully calcified nodules (this criterion is used as a proxy due to the risk of being an infection or metastasis)\n* Have one or more additional nodules where any of the following applies:\n\n  * Are already undergoing follow-up according to pulmonary nodule management standard care\n  * Pure ground glass opacity (GGO) of \\>=5mm in maximum axial diameter for the whole lesion measured using manual electronic callipers\n  * \\>30mm in maximum axial diameter for the whole lesion measured using manual electronic callipers","35 Years",{"count":311,"type":20},2000,"This study is a multi-centre prospective observational cohort study recruiting patients with 5-30mm solid and part-solid pulmonary nodules that have been detected on CT chest scans performed as part of routine practice. The aim is to determine whether physician decision making with the AI-based LCP tool, generates clinical and health-economic benefits over the current standard of care of these patients.",[314,315,316,317],"AI (Artificial Intelligence)","Pulmonary Nodule, Solitary","Pulmonary Nodule, Multiple","Lung Cancer",{"date":295,"type":29},{"date":320,"type":29},"2023-03-23",{"date":231,"type":20},{"name":35,"class":36},10,""]